AS04-adjuvanted human papillomavirus types 16/18 vaccine (Cervarix®): A guide to its use

被引:0
|
作者
Lyseng-Williamson K.A. [1 ]
McKeage K. [1 ]
机构
[1] Adis, 41 Centorian Drive, Mairangi Bay, North Shore 0754, Auckland
关键词
Adis-Clinical-Q-and-A; Cervical-cancer; Cervical-cancer-vaccine; Human-papillomavirus-infections; Human-papillomavirus-vaccine; Human-papillomavirus-vaccine-recombinant-bivalent; Precancerous-conditions;
D O I
10.2165/11208830-000000000-00000
中图分类号
学科分类号
摘要
The AS04-adjuvanted human papillomavirus (HPV) 1618 vaccine is indicated for the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. The vaccine elicits a high immunogenic response and is highly protective against cervical intraepithelial neoplasia and infection. It is also generally well tolerated, and cost effective from a healthcare payer perspective. © 2012 Adis Data Information BV. All rights reserved.
引用
收藏
页码:1 / 6
页数:5
相关论文
共 50 条